



1614
RECEIVED
NOV 21 2001
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: COHN and CARSON

Application No.: 09/658,261

Filed: September 8, 2000

For: **Methods of Treating and Preventing Congestive Heart Failure With Hydralazine Compounds and Isosorbide Dinitrate or Isosorbide Mononitrate**

Attorney Docket No.: 102258.288

Assistant Commissioner of Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants bring to the attention of the Examiner the document listed on the attached PTO-1449 Form.


The submission of this Information Disclosure Statement does not represent that a search has been made and does not constitute an admission that the listed document is material to patentability or that the listed document is prior art.

A copy of the document listed on the attached PTO-1449 Form is submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. Accordingly, no fee is due. In the event that a fee is required, the Commissioner is authorized to charge Deposit Account No. 08-0219.

Applicants respectfully request that the Examiner initial and return a copy of the enclosed PTO-1449 form with the next communication from the Patent Office.

Respectfully submitted,


Edward D. Grieff
Registration No. 38,898

Date: November 15, 2001
HALE and DORR LLP
1455 Pennsylvania Avenue, NW
Washington, DC 20004
Phone: (202) 942-8400